Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

Posted:
17
August 2020

Richmond Pharmacology early phase drug development update.

The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Alnylam's lumasiran a positive scientific opinion through the Early Access to Medicines Scheme (EAMS).

The decision allows patients with the ultra-rare disease primary hyperoxaluria type 1 (PH1) access to the drug before its official approval by the European Commission.

PH1 is an ultra-rare orphan disease affecting around 90 patients in the UK, that causes an abnormal build-up of toxic oxalate in the liver, resulting in painful and recurrent kidney stones and ultimately irreparable damage to the kidneys and other vital organs.

Richmond Pharmacology is proud to have been involved in the early stage of the drug and supported the development through a first-in-human combined healthy volunteer and patient trial.

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more